Landry Robert E 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 18, 2024
Insider Transaction Report
Form 4
Landry Robert E
SVP Fin, Dep CFO
Transactions
- Tax Payment
Common Stock
2024-01-17$932.34/sh−354$330,048→ 22,984 total - Exercise/Conversion
Common Stock
2024-01-17$378.98/sh+500$189,490→ 23,338 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-17−500→ 14,187 totalExercise: $378.98Exp: 2027-12-12→ Common Stock (500 underlying)
Holdings
- 270(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.